CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $68.06 Average Target Price from Analysts

Posted by Francis Steltz on Aug 23rd, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $68.0556.

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, July 8th. Evercore reiterated an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a research note on Monday, May 11th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group set a $80.00 price objective on CRISPR Therapeutics in a research report on Friday, June 12th. Finally, Citigroup upped their price objective on CRISPR Therapeutics from $82.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th.

Get Our Latest Research Report on CRISPR Therapeutics

Insider Buying and Selling

In other news, insider Naimish Patel sold 3,786 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after buying an additional 31,392 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the first quarter worth $861,000. Woodline Partners LP increased its holdings in shares of CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after buying an additional 34,883 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $237,000. Finally, Invesco Ltd. lifted its stake in shares of CRISPR Therapeutics by 138.4% in the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock valued at $3,242,000 after acquiring an additional 38,691 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $59.50 on Thursday. The firm has a 50 day moving average of $53.05 and a 200-day moving average of $52.38. The stock has a market capitalization of $5.75 billion, a PE ratio of -12.50 and a beta of 1.74. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. On average, equities research analysts predict that CRISPR Therapeutics will post -4.47 EPS for the current fiscal year.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.